



# Zilbrysq in Qatar

The MoPH named-patient coordination pathway — indicative 2026

NEUROLOGY · GENERALISED MYASTHENIA GRAVIS (ACHR+)

## The clinical situation

Zilbrysq (zilucoplan) is a macrocyclic peptide terminal complement C5 inhibitor, FDA-approved for generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. Manufactured by UCB, it is delivered as a once-daily subcutaneous self-injection (0.3 mg/kg, weight-based). It carries a US boxed warning regarding serious meningococcal infections, which is why meningococcal vaccination (or antibiotic prophylaxis per labeling) is a gating step before therapy begins. Internationally, equivalent manufacturer risk-minimisation measures apply.

## The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your neurologist confirms AChR-antibody positivity, gMG diagnosis, MGFA classification, and writes the rationale letter.
- 2 Meningococcal vaccination & risk minimisation.** Vaccination at least 2 weeks before first dose, or antibiotic prophylaxis per FDA labeling.
- 3 MoPH named-patient application.** Physician or hospital pharmacy files dossier: rationale, patient reference, vaccination documentation, daily dosing plan.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed specialty wholesale partner, aligned with the manufacturer's controlled-distribution model.
- 5 Arrival & self-injection training.** Cold-chain (2–8°C) delivery; your clinic trains the patient or caregiver; daily maintenance is self-administered.

## Indicative economics

**Reference US cash-pay range:** USD 500,000–700,000 annualised at US list (daily SC dosing; Reserve Meds provides a transparent delivered quote at intake).

## Indicative first-dose timing

**7–14 days** from a complete MoPH application to first dispensation; vaccination lead time may extend this. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your neurologist and MoPH review, including the meningococcal-infection risk-minimisation block. **Logistics.** Cold-chain (2–8°C) shipment with continuous temperature monitoring and importer-of-record handling. **Concierge case lead.** Named point of contact for family and care team. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Zilbrysq × Qatar first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/zilbrysq-qatar.html](https://reservemed.com/access-guides/zilbrysq-qatar.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team